Breaking the cycle of transfusion dependence in β-thalassaemia

Kevin H M Kuo¹, Stéphanie Forté²

Affiliations

¹ Division of Haematology, University of Toronto, Toronto, ON M5G 1L7, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address: kevin.kuo@utoronto.ca.
² Division of Haematology and Medical Oncology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Medicine, University of Montreal, Montreal, Canada.

PMID: 39615986
DOI: 10.1016/S0140-6736(24)02514-5

Comment

Breaking the cycle of transfusion dependence in β-thalassaemia

Kevin H M Kuo et al. Lancet. 2024.

. 2024 Nov 30;404(10468):2134-2135.

doi: 10.1016/S0140-6736(24)02514-5.

Authors

Kevin H M Kuo¹, Stéphanie Forté²

Affiliations

¹ Division of Haematology, University of Toronto, Toronto, ON M5G 1L7, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address: kevin.kuo@utoronto.ca.
² Division of Haematology and Medical Oncology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Medicine, University of Montreal, Montreal, Canada.

PMID: 39615986
DOI: 10.1016/S0140-6736(24)02514-5

No abstract available

PubMed Disclaimer

Conflict of interest statement

KHMK has received grants from Agios Pharmaceuticals and Pfizer; consulting fees from Alexion Pharmaceuticals, Agios Pharmaceuticals, Biossil, Bristol Myers Squibb, Forma Therapeutics, Pfizer, NovoNordisk, and Vertex; honoraria from Agios Pharmaceuticals, and Bristol Myers Squibb; and was a member of the data safety monitoring board for Sangamo (NCT03653247). SF has received consulting fees from Bristol Myers Squibb, Pfizer, NovoNordisk, and Vertex.

Comment on

Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
Kwiatkowski JL, Walters MC, Hongeng S, Yannaki E, Kulozik AE, Kunz JB, Sauer MG, Thrasher AJ, Thuret I, Lal A, Tao G, Ali S, Thakar HL, Elliot H, Lodaya A, Lee J, Colvin RA, Locatelli F, Thompson AA. Kwiatkowski JL, et al. Lancet. 2024 Nov 30;404(10468):2175-2186. doi: 10.1016/S0140-6736(24)01884-1. Epub 2024 Nov 8. Lancet. 2024. PMID: 39527960 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Breaking the cycle of transfusion dependence in β-thalassaemia

Affiliations

Breaking the cycle of transfusion dependence in β-thalassaemia

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

LinkOut - more resources

Full Text Sources